Intranigral Transplantation of Epigenetically Induced BDNF-Secreting Human Mesenchymal Stem Cells: Implications for Cell-Based Therapies in Parkinson's Disease

Rodrigo Somoza, Carlos Juri, Mauricio Baes, Ursula Wyneken, Francisco Javier Rubio*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

60 Scopus citations


It is thought that the ability of human mesenchymal stem cells (hMSC) to deliver neurotrophic factors might be potentially useful for the treatment of neurodegenerative disorders. The aim of the present study was to characterize signals and/or molecules that regulate brain-derived neurotrophic factor (BDNF) protein expression/delivery in hMSC cultures and evaluate the effect of epigenetically generated BDNF-secreting hMSC on the intact and lesioned substantia nigra (SN). We tested 4 different culture media and found that the presence of fetal bovine serum (FBS) decreased the expression of BDNF, whereas exogenous addition of epidermal growth factor (EGF) and basic fibroblast growth factor (bFGF) to serum-free medium was required to induce BDNF release (125 ± 12 pg/day/106 cells). These cells were called hM(N)SC. Although the induction medium inhibited the expression of alpha smooth muscle actin (ASMA), an hMSC marker, and increased the nestin-positive subpopulation of hMSC cultures, the ability to express BDNF was restricted to the nestin-negative subpopulation. One week after transplantation into the SN, the human cells integrated into the surrounding tissue, and some showed a dopaminergic phenotype. We also observed the activation of Trk receptors for neurotrophic factors around the implant site, including the BDNF receptor TrkB. When we transplanted these cells into the unilateral lesioned SN induced by striatal injection of 6-hydroxydopamine (6-OHDA), a significant hypertrophy of nigral tyrosine hydroxylase (TH)+ cells, an increase of striatal TH-staining and stabilization of amphetamine-induced motor symptoms were observed. Therefore, hMSC cultures exposed to the described induction medium might be highly useful as a vehicle for neurotrophic delivery to the brain and specifically are strong candidates for future therapeutic application in Parkinson's disease.

Original languageEnglish
Pages (from-to)1530-1540
Number of pages11
JournalBiology of Blood and Marrow Transplantation
Issue number11
StatePublished - Nov 2010

Bibliographical note

Funding Information:
Financial disclosure: This work was supported in part by grants to F.J.R. from the Fundacion Andes C-14060/60 , Universidad del Desarrollo 80.11.037 , and Anillo ACT09_2006 (to U.W.).


  • Mesenchymal stem cell transplantation
  • Neurotrophins
  • Substantia nigra
  • Trk receptors
  • Unilateral 6-hydroxydopamine lesion


Dive into the research topics of 'Intranigral Transplantation of Epigenetically Induced BDNF-Secreting Human Mesenchymal Stem Cells: Implications for Cell-Based Therapies in Parkinson's Disease'. Together they form a unique fingerprint.

Cite this